DocDollars

Aegerion Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000000128

Total reported 2019–2025
$8.03M
#563 of 2,960 reporting companies — 0% of all reported industry payments
$7.87M in general payments across 622 records, plus $160K in research funding across 103 records.

How it breaks down

General payments $7,868,596
Research funding $159,503

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Aegerion Pharmaceuticals, Inc. reported $8.03M to US doctors and teaching hospitals from 2019 to 2025, ranking #563 of 2,960 reporting companies. 2% of that was research funding and 98% general payments such as consulting, speaking, food and travel. 622 general payment records and 103 research records were filed.

Common questions about Aegerion Pharmaceuticals, Inc.

How much has Aegerion Pharmaceuticals, Inc. paid US doctors?

Aegerion Pharmaceuticals, Inc. reported $8,028,099 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,868,596 in general payments, $159,503 in research funding.

How does Aegerion Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #563 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Aegerion Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.